The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antivirals by targeting the drug-resistant mutants of M2 and the viral polymerase. In this presentation, I will introduce our work in designing inhibitors targeting the viral M2-S31N mutant proton channel and the viral polymerase PA-PB1 interactions. The designed M2-S31N inhibitors and the PA-PB1 inhibitors have been shown to inhibit drug resistant influenza viruses with potent antiviral efficacy and a high selectivity index.
Molecular Biology
Clinical Diagnostics
Immunology
Microbiology
Biotechnology
Infectious Disease
Cancer Research
Laboratory Testing
Biochemistry
Gene Expression
Animal Research
Dna
Biomarkers
Genomics
Cancer Diagnostics
Asia52%
North America43%
Europe4%
Website Visitors83%
Email Promotions13%
Social Media Promotions4%
Student30%
Research Scientist15%
Medical Laboratory Technician15%
Medical Doctor/Specialist10%
Educator/Faculty10%
Clinical Laboratory Scientist5%
Microbiologist5%
Veterinarian5%
Lab Management5%
Academic Institution48%
Medical School9%
Research Institute9%
Clinical Laboratory9%
Hospital4%
Pharmaceutical Company4%
Medical Center4%
Veterinary School4%
Government4%
Manufacturer - Other4%